Which has stronger valuation & earnings, CLDX or RGEN?

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celldex Therapeutics $1.54M 1,993.34 -$258.76M -$4.26 N/A Repligen $738.26M 11.02 $48.89M $0.90 160.27

Celldex Therapeutics (CLDX) Competitors

$39.11 +0.13 (+0.33%)

Closing price 07/10/2026 04:00 PM Eastern

Extended Trading

$39.10 -0.01 (-0.03%)

As of 07/10/2026 04:52 PM Eastern

Compare

CLDX vs. BMRN, HALO, ALKS, RGEN, and LGND

Should you buy Celldex Therapeutics stock or one of its competitors? MarketBeat compares Celldex Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Celldex Therapeutics include BioMarin Pharmaceutical (BMRN), Halozyme Therapeutics (HALO), Alkermes (ALKS), Repligen (RGEN), and Ligand Pharmaceuticals (LGND). These companies are all part of the "biotechnology" industry.

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Celldex Therapeutics (NASDAQ:CLDX) and BioMarin Pharmaceutical (NASDAQ:BMRN) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, profitability, risk, institutional ownership, valuation, dividends, media sentiment and earnings.

BioMarin Pharmaceutical has a net margin of 8.29% compared to Celldex Therapeutics' net margin of 0.00%. BioMarin Pharmaceutical's return on equity of 6.50% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
BioMarin Pharmaceutical	8.29%	6.50%	5.07%

BioMarin Pharmaceutical has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than BioMarin Pharmaceutical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A
BioMarin Pharmaceutical	$3.22B	3.55	$348.90M	$1.37	43.15

In the previous week, BioMarin Pharmaceutical had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for BioMarin Pharmaceutical and 1 mentions for Celldex Therapeutics. Celldex Therapeutics' average media sentiment score of 0.00 beat BioMarin Pharmaceutical's score of -0.50 indicating that Celldex Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Celldex Therapeutics	Neutral
BioMarin Pharmaceutical	Negative

Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market. Comparatively, BioMarin Pharmaceutical has a beta of 0.24, meaning that its share price is 76% less volatile than the broader market.

98.7% of BioMarin Pharmaceutical shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by insiders. Comparatively, 0.9% of BioMarin Pharmaceutical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Celldex Therapeutics currently has a consensus price target of $49.30, suggesting a potential upside of 26.05%. BioMarin Pharmaceutical has a consensus price target of $88.50, suggesting a potential upside of 49.70%. Given BioMarin Pharmaceutical's higher probable upside, analysts plainly believe BioMarin Pharmaceutical is more favorable than Celldex Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
BioMarin Pharmaceutical	0 Sell rating(s)	7 Hold rating(s)	15 Buy rating(s)	2 Strong Buy rating(s)	2.79

Summary

BioMarin Pharmaceutical beats Celldex Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Halozyme Therapeutics (NASDAQ:HALO) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, risk, dividends, earnings, institutional ownership, analyst recommendations, valuation and media sentiment.

Halozyme Therapeutics has a net margin of 23.13% compared to Celldex Therapeutics' net margin of 0.00%. Halozyme Therapeutics' return on equity of 187.91% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Halozyme Therapeutics	23.13%	187.91%	21.92%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Halozyme Therapeutics has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Halozyme Therapeutics	$1.40B	6.47	$316.89M	$2.78	27.41
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

97.8% of Halozyme Therapeutics shares are held by institutional investors. 2.5% of Halozyme Therapeutics shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.

In the previous week, Halozyme Therapeutics had 14 more articles in the media than Celldex Therapeutics. MarketBeat recorded 15 mentions for Halozyme Therapeutics and 1 mentions for Celldex Therapeutics. Halozyme Therapeutics' average media sentiment score of 1.19 beat Celldex Therapeutics' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Halozyme Therapeutics	Positive
Celldex Therapeutics	Neutral

Halozyme Therapeutics presently has a consensus target price of $81.60, indicating a potential upside of 7.09%. Celldex Therapeutics has a consensus target price of $49.30, indicating a potential upside of 26.05%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Halozyme Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Halozyme Therapeutics	1 Sell rating(s)	4 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.54
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Halozyme Therapeutics has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, meaning that its share price is 10% less volatile than the broader market.

Summary

Halozyme Therapeutics beats Celldex Therapeutics on 10 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Alkermes?

Alkermes (NASDAQ:ALKS) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their profitability, risk, earnings, valuation, analyst recommendations, media sentiment, dividends and institutional ownership.

Alkermes has a beta of 0.34, suggesting that its share price is 66% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market.

Alkermes has a net margin of 9.78% compared to Celldex Therapeutics' net margin of 0.00%. Alkermes' return on equity of 9.26% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alkermes	9.78%	9.26%	5.66%
Celldex Therapeutics	N/A	-50.72%	-46.59%

Alkermes presently has a consensus target price of $49.63, indicating a potential downside of 4.46%. Celldex Therapeutics has a consensus target price of $49.30, indicating a potential upside of 26.05%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Alkermes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alkermes	1 Sell rating(s)	4 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.72
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Alkermes has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Alkermes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alkermes	$1.48B	5.87	$241.66M	$0.90	57.71
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

95.2% of Alkermes shares are owned by institutional investors. 4.6% of Alkermes shares are owned by company insiders. Comparatively, 5.2% of Celldex Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

In the previous week, Alkermes had 6 more articles in the media than Celldex Therapeutics. MarketBeat recorded 7 mentions for Alkermes and 1 mentions for Celldex Therapeutics. Alkermes' average media sentiment score of 0.50 beat Celldex Therapeutics' score of 0.00 indicating that Alkermes is being referred to more favorably in the media.

Company	Overall Sentiment
Alkermes	Neutral
Celldex Therapeutics	Neutral

Summary

Alkermes beats Celldex Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Celldex Therapeutics compare to Repligen?

Celldex Therapeutics (NASDAQ:CLDX) and Repligen (NASDAQ:RGEN) are both mid-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Celldex Therapeutics presently has a consensus price target of $49.30, indicating a potential upside of 26.05%. Repligen has a consensus price target of $165.00, indicating a potential upside of 14.39%. Given Celldex Therapeutics' higher probable upside, equities research analysts clearly believe Celldex Therapeutics is more favorable than Repligen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82
Repligen	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	2 Strong Buy rating(s)	2.89

Repligen has a net margin of 6.73% compared to Celldex Therapeutics' net margin of 0.00%. Repligen's return on equity of 4.88% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celldex Therapeutics	N/A	-50.72%	-46.59%
Repligen	6.73%	4.88%	3.48%

Celldex Therapeutics has a beta of 0.9, suggesting that its share price is 10% less volatile than the broader market. Comparatively, Repligen has a beta of 1.06, suggesting that its share price is 6% more volatile than the broader market.

In the previous week, Repligen had 3 more articles in the media than Celldex Therapeutics. MarketBeat recorded 4 mentions for Repligen and 1 mentions for Celldex Therapeutics. Repligen's average media sentiment score of 1.08 beat Celldex Therapeutics' score of 0.00 indicating that Repligen is being referred to more favorably in the news media.

Company	Overall Sentiment
Celldex Therapeutics	Neutral
Repligen	Positive

97.6% of Repligen shares are held by institutional investors. 5.2% of Celldex Therapeutics shares are held by company insiders. Comparatively, 0.6% of Repligen shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Repligen has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Repligen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A
Repligen	$738.26M	11.02	$48.89M	$0.90	160.27

Summary

Repligen beats Celldex Therapeutics on 14 of the 17 factors compared between the two stocks.

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Ligand Pharmaceuticals (NASDAQ:LGND) and Celldex Therapeutics (NASDAQ:CLDX) are both mid-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, valuation, institutional ownership, earnings, profitability, dividends, media sentiment and analyst recommendations.

91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 7.0% of Ligand Pharmaceuticals shares are held by insiders. Comparatively, 5.2% of Celldex Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Ligand Pharmaceuticals has higher revenue and earnings than Celldex Therapeutics. Celldex Therapeutics is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Ligand Pharmaceuticals	$268.09M	23.64	$124.45M	$7.37	42.91
Celldex Therapeutics	$1.54M	1,993.34	-$258.76M	-$4.26	N/A

Ligand Pharmaceuticals has a beta of 1.1, suggesting that its stock price is 10% more volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.9, suggesting that its stock price is 10% less volatile than the broader market.

Ligand Pharmaceuticals has a net margin of 55.95% compared to Celldex Therapeutics' net margin of 0.00%. Ligand Pharmaceuticals' return on equity of 16.19% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Ligand Pharmaceuticals	55.95%	16.19%	11.13%
Celldex Therapeutics	N/A	-50.72%	-46.59%

In the previous week, Ligand Pharmaceuticals had 13 more articles in the media than Celldex Therapeutics. MarketBeat recorded 14 mentions for Ligand Pharmaceuticals and 1 mentions for Celldex Therapeutics. Ligand Pharmaceuticals' average media sentiment score of 0.95 beat Celldex Therapeutics' score of 0.00 indicating that Ligand Pharmaceuticals is being referred to more favorably in the media.

Company	Overall Sentiment
Ligand Pharmaceuticals	Positive
Celldex Therapeutics	Neutral

Ligand Pharmaceuticals presently has a consensus price target of $292.86, suggesting a potential downside of 7.39%. Celldex Therapeutics has a consensus price target of $49.30, suggesting a potential upside of 26.05%. Given Celldex Therapeutics' higher possible upside, analysts clearly believe Celldex Therapeutics is more favorable than Ligand Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Ligand Pharmaceuticals	0 Sell rating(s)	1 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.88
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

Summary

Ligand Pharmaceuticals beats Celldex Therapeutics on 13 of the 17 factors compared between the two stocks.

Get Celldex Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CLDX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CLDX vs. The Competition

Export

Metric	Celldex Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$3.06B	$3.78B	$7.12B	$12.61B
Dividend Yield	N/A	2.17%	2.68%	7.83%
P/E Ratio	-9.18	21.27	27.19	24.56
Price / Sales	1,993.34	323.90	590.19	121.71
Price / Cash	N/A	147.64	49.34	60.04
Price / Book	4.93	8.41	10.90	6.39
Net Income	-$258.76M	$23.85M	$3.57B	$331.44M
7 Day Performance	1.93%	-0.76%	-0.25%	0.37%
1 Month Performance	30.54%	8.80%	4.53%	0.54%
1 Year Performance	70.71%	53.61%	29.18%	21.93%

Celldex Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CLDX Celldex Therapeutics	1.7981 of 5 stars	$39.11 +0.3%	$49.30 +26.1%	+72.4%	$3.06B	$1.54M	N/A	150
BMRN BioMarin Pharmaceutical	4.3534 of 5 stars	$58.79 -0.3%	$88.67 +50.8%	+0.5%	$11.40B	$3.22B	42.91	3,221	News Coverage Analyst Forecast
HALO Halozyme Therapeutics	4.0085 of 5 stars	$80.78 +1.7%	$81.60 +1.0%	+32.2%	$9.42B	$1.40B	29.06	390	Positive News Insider Trade
ALKS Alkermes	1.7266 of 5 stars	$55.14 +1.0%	$49.63 -10.0%	+70.5%	$9.10B	$1.48B	61.27	2,050
RGEN Repligen	3.2457 of 5 stars	$141.46 -0.7%	$165.00 +16.6%	+7.6%	$8.03B	$738.26M	157.18	2,000	Analyst Upgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CLDX) was last updated on 7/11/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Celldex Therapeutics (CLDX) Competitors

CLDX vs. BMRN, HALO, ALKS, RGEN, and LGND

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Summary

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Summary

How does Celldex Therapeutics compare to Alkermes?

Summary

How does Celldex Therapeutics compare to Repligen?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Celldex Therapeutics (CLDX) Competitors

CLDX vs. BMRN, HALO, ALKS, RGEN, and LGND

How does Celldex Therapeutics compare to BioMarin Pharmaceutical?

Is CLDX or BMRN more profitable?

Which has better earnings & valuation, CLDX or BMRN?

Does the media prefer CLDX or BMRN?

Which has more volatility & risk, CLDX or BMRN?

Do insiders & institutionals have more ownership in CLDX or BMRN?

Do analysts rate CLDX or BMRN?

Summary

How does Celldex Therapeutics compare to Halozyme Therapeutics?

Is HALO or CLDX more profitable?

Which has preferable earnings and valuation, HALO or CLDX?

Do institutionals & insiders believe in HALO or CLDX?

Does the media refer more to HALO or CLDX?

Do analysts rate HALO or CLDX?

Which has more volatility & risk, HALO or CLDX?

Summary

How does Celldex Therapeutics compare to Alkermes?

Which has more risk and volatility, ALKS or CLDX?

Is ALKS or CLDX more profitable?

Do analysts rate ALKS or CLDX?

Which has higher earnings & valuation, ALKS or CLDX?

Do institutionals & insiders believe in ALKS or CLDX?

Does the media refer more to ALKS or CLDX?

Summary

How does Celldex Therapeutics compare to Repligen?

Do analysts recommend CLDX or RGEN?

Is CLDX or RGEN more profitable?

Which has more volatility and risk, CLDX or RGEN?

Does the media refer more to CLDX or RGEN?

Do insiders and institutionals have more ownership in CLDX or RGEN?

Which has stronger valuation & earnings, CLDX or RGEN?

Summary

How does Celldex Therapeutics compare to Ligand Pharmaceuticals?

Do insiders and institutionals believe in LGND or CLDX?

Which has preferable earnings & valuation, LGND or CLDX?

Which has more volatility & risk, LGND or CLDX?

Is LGND or CLDX more profitable?

Does the media favor LGND or CLDX?

Do analysts rate LGND or CLDX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CLDX vs. The Competition

Celldex Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools